Literature DB >> 16396957

Complete response to erlotinib treatment in brain metastases from recurrent NSCLC.

C S L Lai, C Boshoff, M Falzon, S M Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16396957      PMCID： PMC2080696          DOI： 10.1136/thx.2005.052233

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  5 in total

1.  A small molecule-kinase interaction map for clinical kinase inhibitors.

Authors:  Miles A Fabian; William H Biggs; Daniel K Treiber; Corey E Atteridge; Mihai D Azimioara; Michael G Benedetti; Todd A Carter; Pietro Ciceri; Philip T Edeen; Mark Floyd; Julia M Ford; Margaret Galvin; Jay L Gerlach; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Michael A Insko; Andiliy G Lai; Jean-Michel Lélias; Shamal A Mehta; Zdravko V Milanov; Anne Marie Velasco; Lisa M Wodicka; Hitesh K Patel; Patrick P Zarrinkar; David J Lockhart
Journal:  Nat Biotechnol       Date:  2005-02-13       Impact factor: 54.908

2.  Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Authors:  Ming-Sound Tsao; Akira Sakurada; Jean-Claude Cutz; Chang-Qi Zhu; Suzanne Kamel-Reid; Jeremy Squire; Ian Lorimer; Tong Zhang; Ni Liu; Manijeh Daneshmand; Paula Marrano; Gilda da Cunha Santos; Alain Lagarde; Frank Richardson; Lesley Seymour; Marlo Whitehead; Keyue Ding; Joseph Pater; Frances A Shepherd
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

3.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

Review 4.  Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

Authors:  William Pao; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

5.  Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).

Authors:  Federico Cappuzzo; Andrea Ardizzoni; Hector Soto-Parra; Cesare Gridelli; Paolo Maione; Marcello Tiseo; Cesare Calandri; Stefania Bartolini; Armando Santoro; Lucio Crinò
Journal:  Lung Cancer       Date:  2003-08       Impact factor: 5.705
  5 in total
  22 in total

Review 1.  Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.

Authors:  Claudia Proto; Martina Imbimbo; Rosaria Gallucci; Angela Brissa; Diego Signorelli; Milena Vitali; Marianna Macerelli; Giulia Corrao; Monica Ganzinelli; Francesca Gabriella Greco; Marina Chiara Garassino; Giuseppe Lo Russo
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 2.  The biology of brain metastases-translation to new therapies.

Authors:  April F Eichler; Euiheon Chung; David P Kodack; Jay S Loeffler; Dai Fukumura; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2011-04-12       Impact factor: 66.675

Review 3.  Current approaches to the treatment of metastatic brain tumours.

Authors:  Taofeek K Owonikoko; Jack Arbiser; Amelia Zelnak; Hui-Kuo G Shu; Hyunsuk Shim; Adam M Robin; Steven N Kalkanis; Timothy G Whitsett; Bodour Salhia; Nhan L Tran; Timothy Ryken; Michael K Moore; Kathleen M Egan; Jeffrey J Olson
Journal:  Nat Rev Clin Oncol       Date:  2014-02-25       Impact factor: 66.675

4.  EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.

Authors:  April F Eichler; Kristopher T Kahle; Daphne L Wang; Victoria A Joshi; Henning Willers; Jeffrey A Engelman; Thomas J Lynch; Lecia V Sequist
Journal:  Neuro Oncol       Date:  2010-07-13       Impact factor: 12.300

5.  Characteristics of patients with brain metastases from lung cancer in a palliative care center.

Authors:  Ryuya Yamanaka; Hatsuyo Koga; Yousuke Yamamoto; Shinichi Yamada; Tomomi Sano; Tetsushi Fukushige
Journal:  Support Care Cancer       Date:  2010-03-10       Impact factor: 3.603

6.  An unusual response with long term survival using erlotinib in NSCLC lung with brain metastases.

Authors:  Madhup Rastogi; Sambit Swarup Nanda; Chandra Prakash; Dinkar Kulshreshtha
Journal:  BMJ Case Rep       Date:  2016-01-04

Review 7.  Acquired resistance to TKIs in solid tumours: learning from lung cancer.

Authors:  D Ross Camidge; William Pao; Lecia V Sequist
Journal:  Nat Rev Clin Oncol       Date:  2014-07-01       Impact factor: 66.675

8.  Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Jumpei Kashima; Yusuke Okuma; Maki Miwa; Yukio Hosomi
Journal:  Med Oncol       Date:  2016-10-18       Impact factor: 3.064

Review 9.  Oral Targeted Therapies and Central Nervous System (CNS) Metastases.

Authors:  Michael P Gabay; Scott M Wirth; Joan M Stachnik; Colleen L Overley; Katie E Long; Linda R Bressler; John L Villano
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

10.  Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation.

Authors:  Katsuhiro Masago; Yosuke Togashi; Masahide Fukudo; Tomohiro Terada; Kaoru Irisa; Yuichi Sakamori; Shiro Fujita; Young Hak Kim; Tadashi Mio; Ken-Ichi Inui; Michiaki Mishima
Journal:  Case Rep Oncol       Date:  2010-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.